Contents
Market Overview
Switzerland has one of the longest-established medical cannabis frameworks in Europe, having first legalised treatment access in 2011 through a system of individual exemptions issued by the national health regulator, Swissmedic. In August 2022, this exemption requirement was abolished, allowing any licensed physician to prescribe medical cannabis without prior government authorisation — a significant step toward simplifying patient access.
Despite this regulatory reform, patient numbers have not increased substantially, largely due to persistent administrative burdens and restrictive reimbursement practices. Access remains dependent on physicians’ willingness to prescribe and insurers’ case-by-case decisions on coverage, creating a system where regulatory legality does not yet translate into broad clinical accessibility.
Switzerland’s medical cannabis supply is provided primarily by a small group of domestic producers supplemented by imports of dronabinol (synthetic THC) and other cannabinoid products, mostly from Germany. Domestic producers are now seeking to scale operations and expand into export markets, notably Germany and the UK, though total volumes remain limited.
Unlike most European markets, Switzerland’s medical cannabis sector is dominated by extracts, which account for approximately 80% of patient treatments, with the remainder consisting of dried flower.
Regulatory Framework
The most significant regulatory shift occurred in August 2022, when Switzerland reclassified medical cannabis from a prohibited narcotic (Schedule D) to a controlled narcotic (Schedule A) under the Narcotics List Ordinance (Betäubungsmittelverordnung).
This change removed the prohibition in Article 8 of the Narcotics Act for medical use, aligning cannabis with the same legal framework governing other controlled narcotics, such as morphine.
Under the revised law:
- Medical cannabis products (flowers, extracts, oils, tinctures, resins) are treated as controlled medicines.
- Companies involved in cultivation, manufacture, distribution, or dispensing must obtain Swissmedic licences for their activities.
- Swissmedic functions as the national Cannabis Agency, overseeing compliance, inspections, and licensing validity (five-year terms).
Cultivation is subject to stringent standards, including traceability, quality control, and pharmaceutical-grade production. While Switzerland’s framework allows both domestic and imported medical cannabis, its licensing process and GMP compliance requirements create a high regulatory barrier to entry.ontrol.oice.ed by the European Medicines Agency, such as Sativex, which remains available under a restricted prescription pathway.
Patient Access
Who Can Prescribe?
Any licensed doctor in Switzerland can prescribe medical cannabis, with no restriction by specialty.
Treatable Pathologies:
Although prescriptions are not limited to specific indications, cannabis is most commonly prescribed for:
- Severe chronic pain
- Spasticity in multiple sclerosis or neurological disorders
- Neuropathic pain
- Cancer-related pain
- Nausea, appetite loss, and cachexia, particularly in chemotherapy patients
Switzerland’s open prescribing model theoretically allows broad patient access, though reimbursement and bureaucratic complexity often limit uptake.
Reimbursement
Public Healthcare (OKP)
Switzerland’s compulsory health insurance (OKP) generally does not cover medical cannabis treatments. However, coverage may be granted under exceptional circumstances, specifically in cases of severe, chronic, or life-threatening disease where standard therapies have failed or are unsuitable.
To qualify for coverage:
- The prescribing physician must demonstrate that medical cannabis provides significant clinical benefit or stabilisation.
- All conventional, approved treatments must have been attempted and deemed ineffective or inappropriate.
- The physician must submit a formal request for cost approval, including a detailed justification and treatment plan.
Each application is evaluated individually, and even successful approvals typically apply to limited treatment durations.
Private Healthcare
Private health insurers may offer more flexibility. Coverage decisions are made case by case, depending on the insurer and the specific policy. Some plans reimburse alternative or complementary therapies — including medical cannabis — if evidence supports cost-effectiveness or clinical necessity.
Products & Prices
Switzerland has an unusually high number of available medical cannabis products relative to its small patient population. Many of these are magistral preparations, compounded by pharmacists from bulk extracts or oils rather than commercially packaged products.
The majority of products prescribed in Switzerland are domestically cultivated and processed, reflecting a growing local supply chain capable of meeting national demand and contributing to early-stage exports.
Product Format Split (March 2025):
- Extracts: 59%
- Flower: 41%
(Source: IG MedCann, 2025)
Average retail prices vary depending on formulation and concentration, with extracts generally priced higher due to production complexity and pharmaceutical-grade certification.
Industry Landscape
The Swiss medical cannabis market is characterised by a small but specialised domestic industry, supported by high regulatory standards, stable governance, and increasing international engagement.
Switzerland’s producers are expanding operations to secure EU-GMP certification and access export markets, particularly in Germany and the United Kingdom, where demand for compliant medical-grade cannabis is strong.
The domestic market remains small but steady, supported by physician familiarity and growing patient awareness. The dominance of extract-based therapies positions Switzerland uniquely among European peers, offering a pharmaceutical-oriented model rather than a consumer-led system.
Outlook
Switzerland’s medical cannabis market demonstrates regulatory maturity but limited scalability. The 2022 reforms removed legal obstacles to prescribing but did not eliminate administrative or financial barriers for patients.
In the coming years, export growth—particularly to Germany and other EU markets—may provide the most significant expansion opportunities for Swiss producers. Domestically, further progress will depend on streamlining reimbursement procedures and enhancing physician education to increase prescription rates.
Switzerland remains a high-compliance, innovation-driven market, balancing small-scale domestic use with growing regional export significance.
